Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 2—February 2024
Research

Evidence of Zika Virus Reinfection by Genome Diversity and Antibody Response Analysis, Brazil

Marcia da Costa Castilho, Ana Maria Bispo de Filippis, Lais Ceschini Machado, Thaise Yasmine Vasconcelos de Lima Calvanti, Morganna Costa Lima, Vagner Fonseca, Marta Giovanetti, Cassia Docena, Armando Menezes Neto, Camila Helena Aguiar Bôtto-Menezes, Edna Oliveira Kara, Rafael de La Barrera, Kayvon Modjarrad, Silvana Pereira Giozza, Gerson Fernando Pereira, Luiz Carlos Junior Alcantara, Nathalie Jeanne Nicole Broutet, Guilherme Amaral Calvet1, Gabriel Luz Wallau1, and Rafael Freitas Oliveira Franca1Comments to Author 
Author affiliations: Tropical Medicine Foundation Doctor Heitor Vieira Dourado, Manaus, Brazil (M. da Costa Castilho, C.H.A. Bôtto-Menezes); Oswaldo Cruz Foundation, Rio de Janeiro, Brazil (A.M.B. de Filippis, M. Giovanetti, L.C.J. Alcantara); Oswaldo Cruz Foundation, Recife, Brazil (L.C. Machado, T.Y.V. de L. Calvanti, M.C. Lima, C. Docena, A.M. Neto, G.A. Calvet, G.L. Wallau, R.F.O. Franca); Organização Pan-Americana da Saúde/Organização Mundial da Saúde, Brasília, Brazil (V. Fonseca); University of Campus Bio-Medico di Roma, Rome, Italy (M. Giovanetti); World Health Organization, Geneva, Switzerland (E.O. Kara, N.J.N. Broutet); Walter Reed Army Institute of Research, Silver Spring, Maryland, USA (R. de La Barrera, K. Modjarrad); Department of Chronic Condition Diseases and Sexually Transmitted Infections, Brasília, Brazil (S.P. Giozza, G.F. Pereira); National Reference Center for Tropical Infectious Diseases, Hamburg, Germany (G.L. Wallau)

Main Article

Table 2

Characteristics of participants included in study of genomic analysis of Zika virus reinfection, Brazil

Characteristics at enrollment No. (%) participants, n = 135
Age group, y
18–30 45 (33.2)
31–60 84 (62.2)
>60
 6 (4.4)
Sex
M 45 (33.3)
F
 90 (66.7)
Days after symptom onset*
0–2 44 (32.6)
3–5 68 (50.4)
6–8 22 (16.3)
9–11
 1 (0.7)
Clinical signs*
Macular or papular rash 133 (98.5)
Itching 126 (93.3)
Fever 116 (85.9)
Arthralgia 108 (80)
Nonpurulent conjunctivitis 100 (74.1)
Periarticular edema 92 (68.1)

*Reported at screening visit, which did not require enrollment.

Main Article

1These authors contributed equally to this article.

Page created: January 09, 2024
Page updated: January 24, 2024
Page reviewed: January 24, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external